Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 15;16(1):62-64.
doi: 10.17161/kjm.vol16.18940. eCollection 2023.

Effects of Smoking on Outcomes of Thyroid Eye Disease Treated with Teprotumumab: A Retrospective Cohort Study

Jordan Miller O'Dell  1 , Caroline C Mussatto  1 , Rachel L Chu  1 , Mohammed Q Al-Sabbagh  1 , Peter J Timoney  2 , Jason A Sokol  1
Affiliations

Effects of Smoking on Outcomes of Thyroid Eye Disease Treated with Teprotumumab: A Retrospective Cohort Study

Jordan Miller O'Dell et al. Kans J Med. .

Abstract

Introduction: Smoking has been demonstrated to worsen the disease process and conventional treatment outcomes of thyroid eye disease. However, the effects of smoking on outcomes of thyroid eye disease treated with the novel therapeutic teprotumumab are currently unknown. Our study compares response to teprotumumab treatment between smokers and non-smokers with thyroid eye disease.

Methods: A single-center, retrospective cohort study was conducted. Inclusion criteria were patients diagnosed with thyroid eye disease who had started or completed therapy with teprotumumab at the time of our data collection. Main outcome measures included reduction in clinical activity score, diplopia, and proptosis.

Results: All smokers had type 2 thyroid eye disease prior to treatment and demonstrated less improvement in diplopia, proptosis, and overall clinical activity score compared to non-smokers with thyroid eye disease. There was no significant difference between smokers and non-smokers in baseline variables (sex, thyroid stimulating hormone (TSH), thyroxine (T4), triiodothyronine (T3), number of infusions completed). Data analysis revealed a statistically significant difference in proptosis reduction between non-smokers and smokers.

Conclusions: Smoking is a modifiable risk factor which portends a worse response to treatment of thyroid eye disease with teprotumumab.

Keywords: Graves orbitopathy; proptosis; smoking; teprotumumab; thyroid eye disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient characteristics in smokers and non-smokers.
See this image and copyright information in PMC

References

    1. Li Z, Cestari DM, Fortin E. Thyroid eye disease: What is new to know? Curr Opin Ophthalmol. 2018;29(6):528–534. - PubMed
    1. Thornton J, Kelly SP, Harrison RA, Edwards R. Cigarette smoking and thyroid eye disease: A systematic review. Eye (Lond) 2007;21(9):1135–1145. - PubMed
    1. Gandhi R, Durairaj VD, Shah K, et al. [Accessed January 19, 2023];Thyroid Eye Disease. 2023 January 12; https://eyewiki.org/Thyroid_Eye_Disease .
    1. Douglas RS, Wang Y, Dailey RA, et al. Teprotumumab in clinical practice: Recommendations and considerations from the OPTIC trial investigators. J Neuroophthalmol. 2021;41(4):461–468. - PMC - PubMed
    1. Sokol JA, Foulks GN, Haider A, Nunery WR. Ocular surface effects of thyroid disease. Ocul Surf. 2010;8(1):29–39. - PubMed

LinkOut - more resources